Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)

Detalles Bibliográficos
Autor principal: Moon, Jun Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2019
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943264/
https://www.ncbi.nlm.nih.gov/pubmed/31902149
http://dx.doi.org/10.4093/dmj.2019.0207
_version_ 1783484852711981056
author Moon, Jun Sung
author_facet Moon, Jun Sung
author_sort Moon, Jun Sung
collection PubMed
description
format Online
Article
Text
id pubmed-6943264
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-69432642020-01-09 Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8) Moon, Jun Sung Diabetes Metab J Letter Korean Diabetes Association 2019-12 2019-12-26 /pmc/articles/PMC6943264/ /pubmed/31902149 http://dx.doi.org/10.4093/dmj.2019.0207 Text en Copyright © 2019 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter
Moon, Jun Sung
Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_full Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_fullStr Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_full_unstemmed Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_short Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_sort letter: dipeptidyl peptidase-4 inhibitors versus other antidiabetic drugs added to metformin monotherapy in diabetic retinopathy progression: a real world-based cohort study (diabetes metab j 2019;43:640–8)
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943264/
https://www.ncbi.nlm.nih.gov/pubmed/31902149
http://dx.doi.org/10.4093/dmj.2019.0207
work_keys_str_mv AT moonjunsung letterdipeptidylpeptidase4inhibitorsversusotherantidiabeticdrugsaddedtometforminmonotherapyindiabeticretinopathyprogressionarealworldbasedcohortstudydiabetesmetabj2019436408

Ejemplares similares